Identification and Quantification of Necroptosis Landscape on Therapy and Prognosis in Kidney Renal Clear Cell Carcinoma.

Abstract

Kidney renal clear cell carcinoma (KIRC) has high morbidity and gradually increased in recent years, and the rate of progression once relapsed is high. At present, owing to lack of effective prognosis predicted markers and post-recurrence drug selection guidelines, the prognosis of KIRC patients is greatly affected. Necroptosis is a regulated form of cell necrosis in a way that is independent of caspase. Induced necroptosis is considered an effective strategy in chemotherapy and targeted drugs, and it can also be used to improve the efficacy of immunotherapy. Herein, we quantified the necroptosis landscape of KIRC patients from The Cancer Genome Atlas (TCGA) database and divided them into two distinct necroptosis-related patterns (C1 and C2) through the non-negative matrix factorization (NMF) algorithm. Multi-analysis revealed the differences in clinicopathological characteristics and tumor immune microenvironment (TIME). Then, we constructed the NRG prognosis signature (NRGscore), which contained 10 NRGs (PLK1, APP, TNFRSF21, CXCL8, MYCN, TNFRSF1A, TRAF2, HSP90AA1, STUB1, and FLT3). We confirmed that NRGscore could be used as an independent prognostic marker for KIRC patients and performed excellent stability and accuracy. A nomogram model was also established to provide a more beneficial prognostic indicator for the clinic. We found that NRGscore was significantly correlated with clinicopathological characteristics, TIME, and tumor mutation burden (TMB) of KIRC patients. Moreover, NRGscore had effective guiding significance for immunotherapy, chemotherapy, and targeted drugs.

• Authors: Sheng Xin, Jiaquan Mao, Chen Duan, Jiaxin Wang, Yuchao Lu, Jun Yang, Jia Hu, Xiaming Liu, Wei Guan, Tao Wang, Shaogang Wang, Jihong Liu, Wen Song, Xiaodong Song
• Journal: Frontiers in genetics (Front Genet) Vol. 13 Pg. 832046 ( 2022) ISSN: 1664-8021 [Print] Switzerland
• PMID: 35237304 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Xin, Mao, Duan, Wang, Lu, Yang, Hu, Liu, Guan, Wang, Wang, Liu, Song and Song.